Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLU156 versus Coartem for uncomplicated Plasmodium falciparum malaria
2022-002675-10Phase 3
- Sponsor
- Novartis
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ganaplacide + lumefantrine-SDF and lumefantrine in Malaria and malaria (3 arms), sponsored by Novartis. Primary endpoint: PCR-corrected ACPR at Day 29.
02
Drugs
ganaplacide + lumefantrine-SDFlumefantrine
03
Conditions
Malariamalaria
Beyond the preview
Go deeper on 2022-002675-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002675-10.